Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications

Abstract

In the present study, a nanoapatite-mediated delivery system for imatinib has been proposed. Nanohydroxyapatite (nHAp) was obtained by co-precipitation method, and its physicochemical properties in combination with imatinib (IM) were studied by means of XRPD (X-ray Powder Diffraction), SEM-EDS (Scanning Electron Microscopy-Energy Dispersive X-ray Spectroscopy), FT-IR (Fourier-Transform Infrared Spectroscopy), absorption spectroscopy as well as DLS (Dynamic Light Scattering) techniques. The obtained hydroxyapatite was defined as nanosized rod-shaped particles with high crystallinity. The amorphous imatinib was obtained by conversion of its crystalline form. The beneficial effects of amorphous pharmaceutical agents have been manifested in the higher dissolution rate in body fluids improving their bioavailability. Imatinib-to-hydroxyapatite interactions on the surface were confirmed by SEM images as well as absorption and FT-IR spectroscopy. The cytotoxicity of the system was tested on NI-1, L929, and D17 cell lines. The effectiveness of imatinib was not affected by nHAp modification. The calculated IC50 values for drug-modified nHAp were similar to those for the drug itself. However, higher cytotoxicity was observed at higher concentrations of imatinib, in comparison with the drug alone.

Imatinib-Functionalized Galactose Hydrogels Loaded with Nanohydroxyapatite as a Drug Delivery System for Osteosarcoma: In Vitro Studies

“…This observation was also noted in our previous paper regarding the nanoapatite-mediated delivery system for imatinib. 28 Second, in the hydrogel in which hydroxyapatite was dispersed, distinct peaks derived from nHAp were seen at 2θ equal to 25.5, 28.3, 29.1, 31.4, 32.5, 33.7, 39.3, 46.2, 49.1, and 52.6°. Moreover, all peaks observed in the nHAp/IM/galactose hydrogel and nHAp correspond to the peak position for the theoretical hexagonal hydroxyapatite (ICSD−26204 29 ).…”

“…A similar observation was found in our previous research concerning time-dependent fluconazole release from the galactose hydrogels loaded and unloaded with nHAp . Moreover, the nHAp nanoparticle-mediated imatinib system was also tested previously, revealing that 100% of IM was achieved in PBS after 45 min of nHAp/IM incubation and 88% of the drug was released during the first 5 min . In this study, 60% of the drug was released after 5 min of experimental time.…”

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

“…In particular, Sobierajska et al [ 99 ] prepared nanoparticles of hydroxyapatite (nHAp, Ca 10 (PO 4 ) 6 (OH) 2 ), whose physicochemical properties were studied by means of XRPD (X-ray Powder Diffraction), SEM–EDS (Scanning Electron Microscopy–Energy Dispersive X-ray Spectroscopy), FT-IR (Fourier-Transform Infrared Spectroscopy) and DLS (Dynamic Light Scattering) techniques. During the preparation of this nanocarrier drug, a conversion from crystalline to amorphous form occurred, contributing to its better solubility and higher dissolution rate in body fluids, improving drug bioavailability.…”

The Janus Nature of Nanohydroxyapatite in Tumor Progression

“…[24] Apart from being simple drug vehicles, nHAP also possesses antitumor activities both in vitro and in vivo. [25,26] Recently, it has been shown that nHAP significantly inhibits the proliferation of different types of cancer cells, such as hepatoma, gastric cancer, colon cancer, melanoma, breast cancer and glioma cells. [27] Figure 2 depicts the application of nHAP in inhibiting tumor.…”